EU approves AstraZeneca’s Lynparza for patients with germline BRCA-mutated HER2-negative… EP News Bureau Aug 5, 2022 It is the first and only approved medicine targetting BRCA mutations in early breast cancer
European Commission approves Roche’s Tecentriq as adjuvant treatment for early-stage NSCLC EP News Bureau Jun 9, 2022 The approval marks Tecentriq’s sixth lung cancer indication in Europe
